PMC6778423_01
Schematic Timeline of the Clinical Progression of Symptoms, Investigations and Treatment Received over a 12-Year Period. X-axis, progression of years; Blue boxes, progression of symptoms; Purple boxes, trend of antibody titres; Green boxes, treatment given; anti-GAD, anti-glutamic acid decarboxylase; IVIg, intravenous immunoglobulin.
tre-09-677-g001.jpg
PMC6778423_01_tre-09-677-g001.jpg
f0001
CSF investigations, including serum copper, ataxia genetics screen, anti-tissue transglutaminase (TTG), -Caspr, -Lgi1, -Purkinje cell, -Hu, -Yo and -Ri antibodies, were negative or within normal limits. CSF anti-GAD antibody titres were not repeated after their initial measurement at presentation (53.4 mu/ml, 2002; Figure 1).
PMC6778423_02